SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Mirtazapine Disintegrating Formulation

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mirtazapine Disintegrating Formulation

Manufacturer or supplier’s details
Company : Organon & Co.
Address : 30 Hudson Street, 33nd floor
          Jersey City, New Jersey, U.S.A  07302
Telephone : 551-430-6000
Emergency telephone number : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

| Appearance | powder |
| Colour     | No data available |
| Odour      | No data available |

Harmful if swallowed. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.

GHS Classification

Acute toxicity (Oral) : Category 4
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure : Category 2
Short-term (acute) aquatic hazard : Category 3
Long-term (chronic) aquatic hazard : Category 3

GHS label elements

Hazard pictograms : 

Signal word : Warning
SAFETY DATA SHEET according to GB/T 16483 and GB/T 17519

Mirtazapine Disintegrating Formulation

Hazard statements:
- H302 Harmful if swallowed.
- H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
- H373 May cause damage to organs through prolonged or repeated exposure.
- H412 Harmful to aquatic life with long lasting effects.

Precautionary statements:
- Prevention:
  - P201 Obtain special instructions before use.
  - P202 Do not handle until all safety precautions have been read and understood.
  - P260 Do not breathe dust.
  - P264 Wash skin thoroughly after handling.
  - P270 Do not eat, drink or smoke when using this product.
  - P273 Avoid release to the environment.
  - P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
- Response:
  - P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.
  - P308 + P313 IF exposed or concerned: Get medical advice/ attention.
- Storage:
  - P405 Store locked up.
- Disposal:
  - P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards:
Not classified based on available information.

Health hazards:
Harmful if swallowed. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards:
Harmful to aquatic life. Harmful to aquatic life with long lasting effects.

Other hazards which do not result in classification:
Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(+/-)-1,2,3,4,10b-Hexahydro-2-</td>
<td>85650-52-8</td>
<td>&gt;= 20 - &lt; 25</td>
</tr>
</tbody>
</table>
4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed: Harmful if swallowed. Suspected of damaging fertility. Suspected of damaging the unborn child. May cause damage to organs through prolonged or repeated exposure. Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES


Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Mirtazapine Disintegrating Formulation

Hazardous combustion products: Carbon oxides
Nitrogen oxides (NOx)
Metal oxides

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions: Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety
practice, based on the results of the workplace exposure assessment.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage: Keep in properly labelled containers.
Store locked up.
Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine</td>
<td>85650-52-8</td>
<td>TWA</td>
<td>25 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>PC-TWA</td>
<td>10 mg/m³</td>
<td>CN OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures: Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment
Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type
Eye/face protection: Wear the following personal protective equipment: Safety goggles
Skin and body protection: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.

Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hand protection
Material: Chemical-resistant gloves
Remarks: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder
Colour: No data available
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Mirtazapine Disintegrating Formulation

10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks.
Avoid dust formation.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact
Mirtazapine Disintegrating Formulation

Acute toxicity
Harmful if swallowed.

**Product:**
Acute oral toxicity: Acute toxicity estimate: 1,588 mg/kg
Method: Calculation method

**Components:**
\((\pm)\)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Acute oral toxicity: LD50 (Rat): 320 - 490 mg/kg

**Citric acid:**
Acute oral toxicity: LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

**Cellulose:**
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

**Magnesium stearate:**
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

**Skin corrosion/irritation**
Not classified based on available information.

**Components:**

**Citric acid:**
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

**Magnesium stearate:**
Mirtazapine Disintegrating Formulation

Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Citric acid:
Species: Rabbit
Result: Irritation to eyes, reversing within 21 days
Method: OECD Test Guideline 405

Magnesium stearate:
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Magnesium stearate:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Method: OECD Test Guideline 406
Result: negative
Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative
Test Type: unscheduled DNA synthesis assay
Test system: mammalian cells
Result: negative
Test Type: sister chromatid exchange assay  
Test system: mammalian cells  
Result: negative

Genotoxicity in vivo  
Test Type: Micronucleus test  
Species: Rat  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Citric acid:**

Genotoxicity in vitro  
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo  
Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Cellulose:**

Genotoxicity in vitro  
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo  
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative
Carcinogenicity
Not classified based on available information.

Components:

\((-/-)\) \textit{1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:}

\begin{itemize}
  \item **Species**: Mouse
  \item **Application Route**: Oral
  \item **Exposure time**: 18 month(s)
  \item **LOAEL**: 200 mg/kg body weight
  \item **Result**: equivocal
  \item **Target Organs**: Liver
\end{itemize}

\begin{itemize}
  \item **Species**: Rat
  \item **Application Route**: Oral
  \item **Exposure time**: 2 Years
  \item **LOAEL**: 20 mg/kg body weight
  \item **Result**: equivocal
  \item **Target Organs**: Liver, Thyroid
\end{itemize}

Cellulose:

\begin{itemize}
  \item **Species**: Rat
  \item **Application Route**: Ingestion
  \item **Exposure time**: 72 weeks
  \item **Result**: negative
\end{itemize}

Reproductive toxicity
Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:

\begin{itemize}
  \item **Effects on fertility**: Test Type: Fertility/early embryonic development
  \item **Species**: Rat
  \item **Application Route**: Oral
  \item **Fertility**: LOAEL: 15 mg/kg body weight
  \item **Symptoms**: Effect on estrous cycle, Increase of early resorptions
  \item **Result**: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.
\end{itemize}

\begin{itemize}
  \item **Effects on foetal development**: Test Type: Development
  \item **Species**: Rat
  \item **Application Route**: Oral
  \item **Developmental Toxicity**: LOAEL: 100 mg/kg body weight
  \item **Result**: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects
\end{itemize}

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 40 mg/kg body weight
Result: No adverse effects, No teratogenic effects

Reproductive toxicity - Assessment:
: Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

Citric acid:
Effects on foetal development:
: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Cellulose:
Effects on fertility:
: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative
Effects on foetal development:
: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Magnesium stearate:
Effects on fertility:
: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials
Effects on foetal development:
: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
May cause damage to organs through prolonged or repeated exposure.

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Exposure routes: Ingestion
Target Organs: Nervous system
Mirtazapine Disintegrating Formulation

Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

\((-/-)\)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

- Species: Rat
  - LOAEL: 120 mg/kg
  - Application Route: Oral
  - Exposure time: 13 Weeks
  - Target Organs: Nervous system

- Species: Dog
  - LOAEL: 15 mg/kg
  - Application Route: Oral
  - Exposure time: 52 Weeks
  - Target Organs: Nervous system

- Species: Dog
  - LOAEL: 20 mg/kg
  - Application Route: Oral
  - Exposure time: 13 Weeks
  - Target Organs: Nervous system, Testis

Symptoms: Tremors

Citric acid:

- Species: Rat
  - NOAEL: 4,000 mg/kg
  - LOAEL: 8,000 mg/kg
  - Application Route: Ingestion
  - Exposure time: 10 Days

Cellulose:

- Species: Rat
  - NOAEL: >= 9,000 mg/kg
  - Application Route: Ingestion
  - Exposure time: 90 Days

Magnesium stearate:

- Species: Rat
  - NOAEL: > 100 mg/kg
  - Application Route: Ingestion
  - Exposure time: 90 Days
  - Remarks: Based on data from similar materials

Aspiration toxicity

Not classified based on available information.
Experience with human exposure

Components:

(+/-)-1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Ingestion: Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

(+/-)-1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l Exposure time: 96 h Method: FDA 4.11
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 19.5 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 3.6 mg/l Exposure time: 31 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 0.32 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms: EC50 (Natural microorganism): > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
NOEC (Natural microorganism): < 100 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209
Citric acid:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Magnesium stearate:
Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Citric acid:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B
Mirtazapine Disintegrating Formulation

12. BIOACCUMULATIVE POTENTIAL

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Bioaccumulation:
- Species: Oncorhynchus mykiss (rainbow trout)
- Bioconcentration factor (BCF): 334
- Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water:
- log Pow: 2.78

Citric acid:
- Partition coefficient: n-octanol/water:
  - log Pow: -1.72

Magnesium stearate:
- Partition coefficient: n-octanol/water:
  - log Pow: > 4

Mobility in soil

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environmental compartments:
- log Koc: 4.48

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

- Waste from residues:
  - Dispose of in accordance with local regulations.
- Contaminated packaging:
  - Empty containers should be taken to an approved waste handling site for recycling or disposal.
  - If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
- Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

**IMDG-Code**
Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**National Regulations**

**GB 6944/12268**
Not regulated as a dangerous good

**Special precautions for user**
Not applicable

15. REGULATORY INFORMATION

**National regulatory information**
**Law on the Prevention and Control of Occupational Diseases**

**The components of this product are reported in the following inventories:**

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

16. OTHER INFORMATION

**Further information**
Sources of key data used to compile the Safety Data Sheet:

**Date format**: yyyy/mm/dd

**Full text of other abbreviations**

- **ACGIH**: USA. ACGIH Threshold Limit Values (TLV)
- **CN OEL**: Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.
- **ACGIH / TWA**: 8-hour, time-weighted average
- **CN OEL / PC-TWA**: Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized Sys-